No Data
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Nurix Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1 Clinical Trial Cancer Data for BTK Degrader NX-5948.
Nurix Therapeutics Announces Webcast To Review New Data From Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sector Update: Health Care Stocks Rise Pre-Bell Thursday
Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe
Unlock the Full List
Bigmoney Dreamer : Already 500% current year where is yearly bottom of strong buy potential
Bigmoney Dreamer : Time to make separate watchlist of strong buys so get better cost price for less red days